tirofiban 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
fibrinogen receptor antagonists (glycoprotein IIb/IIIa receptor antagonists)	2680	144494-65-5

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: tirofiban aggrestat tirofiban hydrochloride tirofiban HCl tirofiban hydrochloride monohydrate L-700,462 aggrastat	a reversible antagonist of fibrinogen binding to the GP IIb/IIIa receptor, the major platelet surface receptor involved in platelet aggregation, when administered intravenously inhibits ex vivo platelet aggregation in a dose- and concentration-dependent manner Molecular weight: 440.60 Formula: C22H36N2O5S CLOGP: 2 LIPINSKI: 0 HAC: 7 HDO: 3 TPSA: 104.73 ALOGS: -5.14 ROTB: 13 Status: OFP Legend: OFP - off patent OFM - off market ONP - on patent

Molecule

Description

Molfile Inchi Smiles

Synonyms:

tirofiban
aggrestat
tirofiban hydrochloride
tirofiban HCl
tirofiban hydrochloride monohydrate
L-700,462
aggrastat

a reversible antagonist of fibrinogen binding to the GP IIb/IIIa receptor, the major platelet surface receptor involved in platelet aggregation, when administered intravenously inhibits ex vivo platelet aggregation in a dose- and concentration-dependent manner

Molecular weight: 440.60
Formula: C22H36N2O5S
CLOGP: 2
LIPINSKI: 0
HAC: 7
HDO: 3
TPSA: 104.73
ALOGS: -5.14
ROTB: 13

Status: OFP

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

Dose	Unit	Route
10	mg	P

ADMET properties:

Show entries

Search:

Property	Value	Reference
EoM (Fraction excreted unchanged in urine)	65 %	Benet LZ, Broccatelli F, Oprea TI
CL (Clearance)	3 mL/min/kg	Lombardo F, Berellini G, Obach RS
BDDCS (Biopharmaceutical Drug Disposition Classification System)	3	Benet LZ, Broccatelli F, Oprea TI
t_half (Half-life)	1.60 hours	Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma)	0.36 %	Lombardo F, Berellini G, Obach RS
Vd (Volume of distribution)	0.34 L/kg	Lombardo F, Berellini G, Obach RS
BA (Bioavailability)	0 %	Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H

Showing 1 to 7 of 7 entries

Previous1Next

Approvals:

Date	Agency	Company	Orphan
May 14, 1998	FDA	MEDICURE

FDA Adverse Event Reporting System (Female)

Show entries

Search:

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Thrombocytopenia	106.38	86.48	43	556	151114	63337309
Angina pectoris	96.89	86.48	27	572	30051	63458372

Showing 1 to 2 of 2 entries

Previous1Next

FDA Adverse Event Reporting System (Male)

Show entries

Search:

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Thrombocytopenia	253.18	54.46	110	885	156137	34799799
Cerebral haemorrhage	70.21	54.46	29	966	34908	34921028
Cardiogenic shock	59.97	54.46	24	971	26594	34929342
Vascular stent thrombosis	57.88	54.46	14	981	2921	34953015

Showing 1 to 4 of 4 entries

Previous1Next

FDA Adverse Event Reporting System (Geriatric)

Show entries

Search:

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Thrombocytopenia	297.77	53.18	129	1407	265130	79477722
Vascular stent thrombosis	127.61	53.18	26	1510	3684	79739168
Coronary artery stenosis	82.31	53.18	23	1513	12461	79730391
Cardiogenic shock	79.54	53.18	30	1506	41884	79700968
Myocardial infarction	73.44	53.18	45	1491	184084	79558768
Pulmonary alveolar haemorrhage	70.48	53.18	20	1516	11437	79731415
Cerebral haemorrhage	70.27	53.18	30	1506	57643	79685209

Showing 1 to 7 of 7 entries

Previous1Next

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Show entries

Search:

Source	Code	Description
ATC	B01AC17	BLOOD AND BLOOD FORMING ORGANS ANTITHROMBOTIC AGENTS ANTITHROMBOTIC AGENTS Platelet aggregation inhibitors excl. heparin
CHEBI has role	CHEBI:48676	fibrin modulating agent
CHEBI has role	CHEBI:50249	anticoagulants
CHEBI has role	CHEBI:50433	platelet glycoprotein-IIb/IIIa receptor antagonists
FDA EPC	N0000175578	Platelet Aggregation Inhibitor
FDA PE	N0000008832	Decreased Platelet Aggregation
MeSH PA	D002317	Cardiovascular Agents
MeSH PA	D005343	Fibrinolytic Agents
MeSH PA	D006401	Hematologic Agents
MeSH PA	D010975	Platelet Aggregation Inhibitors

Showing 1 to 10 of 10 entries

Previous1Next

Drug Use | Suggest Off label Use Form| |View source of the data|

Show entries

Search:

Disease	Relation	SNOMED_ID	DOID
Non-Q wave myocardial infarction	indication	314207007
Acute coronary syndrome	indication	394659003
Percutaneous coronary intervention	indication	415070008
Intracranial hemorrhage	contraindication	1386000
Acute pericarditis	contraindication	15555002
Arteriovenous malformation	contraindication	24551003
Acute nephropathy	contraindication	58574008
Blood coagulation disorder	contraindication	64779008	DOID:1247
Neoplasm of brain	contraindication	126952004	DOID:1319
Bleeding	contraindication	131148009

Showing 1 to 10 of 20 entries

Previous1 2Next

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	3.02	acidic
pKa2	13.5	acidic
pKa3	10.31	Basic

Orange Book patent data (new drug applications)

Show entries

Search:

Formulation strength	Trade name	Applicant	Application number	Approval date	Type	Dose form	Route	Patent number	Patent expiration date	Patent use
EQ 12.5MG BASE/250ML (EQ 0.05MG BASE/ML)	AGGRASTAT	MEDICURE	N020913	April 20, 2000	RX	SOLUTION	INTRAVENOUS	6770660	May 1, 2023	A DOSING REGIMEN OF AGGRASTAT (TIROFIBAN HYDROCHLORIDE)(25MCG/KG FOLLOWED BY 0.15MCG/KG/MIN INFUSION) TO REDUCE THE RATE OF THROMBOTIC CORONARY EVENTS ASSOCIATED WITH ACUTE CORONARY SYNDROME (ACS) IN PATIENTS WITH NON-ST ELEVATION ACS
EQ 12.5MG BASE/50ML (EQ 0.25MG BASE/ML)	AGGRASTAT	MEDICURE	N020912	May 14, 1998	DISCN	INJECTABLE	INJECTION	6770660	May 1, 2023	A DOSING REGIMEN OF AGGRASTAT (TIROFIBAN HYDROCHLORIDE)(25MCG/KG FOLLOWED BY 0.15MCG/KG/MIN INFUSION) TO REDUCE THE RATE OF THROMBOTIC CORONARY EVENTS ASSOCIATED WITH ACUTE CORONARY SYNDROME (ACS) IN PATIENTS WITH NON-ST ELEVATION ACS
EQ 25MG BASE/500ML (EQ 0.05MG BASE/ML)	AGGRASTAT	MEDICURE	N020913	May 14, 1998	DISCN	SOLUTION	INTRAVENOUS	6770660	May 1, 2023	A DOSING REGIMEN OF AGGRASTAT (TIROFIBAN HYDROCHLORIDE)(25MCG/KG FOLLOWED BY 0.15MCG/KG/MIN INFUSION) TO REDUCE THE RATE OF THROMBOTIC CORONARY EVENTS ASSOCIATED WITH ACUTE CORONARY SYNDROME (ACS) IN PATIENTS WITH NON-ST ELEVATION ACS
EQ 3.75MG BASE/15ML (EQ 0.25MG BASE/ML)	AGGRASTAT	MEDICURE	N020912	Aug. 31, 2016	RX	SOLUTION	INJECTION	6770660	May 1, 2023	A DOSING REGIMEN OF AGGRASTAT (TIROFIBAN HYDROCHLORIDE)(25MCG/KG FOLLOWED BY 0.15MCG/KG/MIN INFUSION) TO REDUCE THE RATE OF THROMBOTIC CORONARY EVENTS ASSOCIATED WITH ACUTE CORONARY SYNDROME (ACS) IN PATIENTS WITH NON-ST ELEVATION ACS
EQ 5MG BASE/100ML (EQ 0.05MG BASE/ML)	AGGRASTAT	MEDICURE	N020913	May 17, 2002	RX	SOLUTION	INTRAVENOUS	6770660	May 1, 2023	A DOSING REGIMEN OF AGGRASTAT (TIROFIBAN HYDROCHLORIDE)(25MCG/KG FOLLOWED BY 0.15MCG/KG/MIN INFUSION) TO REDUCE THE RATE OF THROMBOTIC CORONARY EVENTS ASSOCIATED WITH ACUTE CORONARY SYNDROME (ACS) IN PATIENTS WITH NON-ST ELEVATION ACS

Showing 1 to 5 of 5 entries

Previous1Next

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Show entries

Search:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Mechanism action	Bioact source	MoA source
Integrin alpha-IIb/beta-3	Adhesion	P05106 P08514	ITB3_HUMAN ITA2B_HUMAN	INHIBITOR	IC50	7.96		SCIENTIFIC LITERATURE	DRUG LABEL

Showing 1 to 1 of 1 entries

Previous1Next

External reference:

Show entries

Search:

ID	Source
AGG	PDB_CHEM_ID
007531	NDDF
007532	NDDF
108981004	SNOMEDCT_US
11701	MMSL
1269173006	SNOMEDCT_US
150915-40-5	SECONDARY_CAS_RN
187024	RXNORM
252483	MMSL
386953003	SNOMEDCT_US

Showing 1 to 10 of 29 entries

Previous1 2 3Next

Pharmaceutical products:

Show entries

Search:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
AGGRASTAT	HUMAN PRESCRIPTION DRUG LABEL	1	25208-001	INJECTION, SOLUTION	3.75 mg	INTRAVENOUS	NDA	25 sections
AGGRASTAT	HUMAN PRESCRIPTION DRUG LABEL	1	25208-002	INJECTION, SOLUTION	5 mg	INTRAVENOUS	NDA	25 sections
AGGRASTAT	HUMAN PRESCRIPTION DRUG LABEL	1	25208-901	INJECTION, SOLUTION	3.75 mg	INTRAVENOUS	NDA	25 sections
AGGRASTAT	HUMAN PRESCRIPTION DRUG LABEL	1	25208-902	INJECTION, SOLUTION	5 mg	INTRAVENOUS	NDA	25 sections
Tirofiban	Human Prescription Drug Label	1	55150-429	INJECTION, SOLUTION	5 mg	INTRAVENOUS	ANDA	25 sections
Tirofiban	Human Prescription Drug Label	1	55150-430	INJECTION, SOLUTION	12.50 mg	INTRAVENOUS	ANDA	25 sections
Tirofiban hydrochloride	Human Prescription Drug Label	1	68083-145	INJECTION, SOLUTION	12.50 mg	INTRAVENOUS	ANDA	25 sections

Showing 1 to 7 of 7 entries

Previous1Next